Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

This website uses cookies to improve your experience while you are browsing and to help us understand how you use this Website.
By clicking “Accept All” you agree to receive ALL cookies on our Website.
You can reject the cookies that are not “technical and necessary” customizing your choices by clicking on “Cookie settings”.
If you close this banner by clicking the "X" button, default settings will remain in place and you will continue to browse the Website only with “technical and necessary cookies”.
You can review and change your choices at any time by accessing the Management consent panel.
If you would like to learn more about how cookies work on the Website, read our Privacy Policy and Cookies Policy.